NCT02911805 is a NA clinical trial of Aerobic exercise in Vision Disorders, sponsored by VA Office of Research and Development.

Who is sponsoring NCT02911805?

NCT02911805 is sponsored by VA Office of Research and Development.

What drugs are being tested in NCT02911805?

Interventions in NCT02911805: Aerobic exercise, Balance exercise.

What condition does NCT02911805 study?

NCT02911805 studies Vision Disorders.

Is NCT02911805 still recruiting?

NCT02911805 is currently active, enrolled. Last updated 5 December 2025.

Are results published for NCT02911805?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-05 · How we verify

NCT02911805

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation

Active, enrolled NA Results posted Last updated 5 December 2025

What this trial tests

NA trial testing Aerobic exercise in Vision Disorders in 14 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

10 June 2015

Primary endpoint
14 June 2022

28 January 2028

Quick facts

Lead sponsor	VA Office of Research and Development
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Enrollment	14
Start date	10 June 2015
Primary completion	14 June 2022
Estimated completion	28 January 2028
Sites	1 location across United States

Drugs / interventions tested

Aerobic exercise — full drug profile →
Balance exercise

Conditions studied

Vision Disorders — all drugs for Vision Disorders →

Sponsor

VA Office of Research and Development — full company profile →

Who can join

Adults 18 to 89, any sex, with Vision Disorders. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Visual Acuity - Mean Acuity Change Primary · 12 weeks

Early Treatment Diabetic Retinopathy Study (ETDRS) chart was used. Higher scores mean a better outcome. The number of correct responses (e.g., number of letters read correctly) from a subject assessed prior to start of the first session of the the 12 week study was subtracted from the number of correct responses elicited at the end of the last session of the study. The means of these differences for each study group (Balance Training vs Aerobic Exercise) were compared by two-tailed t-test.

Group	Value	95% CI
Aerobic Exercise	7.333	± 8.501
Balance Training	-4.875	± 10.58

Sponsor's own description

This study will determine whether blood biomarker changes predict sight-saving benefits of exercise.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Aerobic exercise

Trials testing the same drug.

NCT07212829 — The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pai · NA · not yet recruiting
NCT07248137 — Acute Effects of Exercise in Peripheral Arterial Disease Patients · NA · not yet recruiting
NCT07428850 — Effect of Aerobic Exercises Versus Low Interval Training on Cardiorespiratory Fitness in School Going Chlidren. · NA · recruiting
NCT07288905 — Exploring the Effects of Exercise Combined With BFRT on Healthy and Patients With CKD · NA · recruiting
NCT07107061 — PILATES AND AEROBIC TRAINING ON BODY COMPOSITION IN YOUNG ADULTS · NA · completed

Other recruiting trials for Vision Disorders

Currently open trials in the same condition.

NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT06992622 — Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis · recruiting
NCT06451172 — Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis · EARLY_PHASE1 · recruiting
NCT04123626 — A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due · Phase 1, PHASE2 · active not recruiting

Other VA Office of Research and Development trials

Trials by the same sponsor.

NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care · Phase 1 · not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran · NA · not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness · NA · not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans · NA · not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02911805 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 5 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02911805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing